Compared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.
Ian E. Krop, MD, PhD
Advertisement
Articles by Ian E. Krop, MD, PhD
Advertisement
Latest Updated Articles
Datopotamab Deruxtecan Demonstrates Manageable Safety Profile in TNBCPublished: January 10th 2022 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Improving Access to Supportive Care on an Organizational Level, With Korie Bigbee
2
Managing Acute and Late Adverse Effects of Breast Cancer Radiation
3
The “Owners” and “Managers” in the Peer-to-Peer Process: What an APP Should Know
4
An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team
5
